VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce it has signed a letter of intent (the "LOI") with dicentra Inc. ("dicentra") to establish a regulatory services partnership (the "Partnership") under which dicentra will provide a suite of services to support Abattis's current and future regulatory and compliance needs. Pursuant to the LOI, Abattis and dicentra have agreed to negotiate in good faith the terms of a definitive agreement respecting the Partnership, which agreement will include representations, warranties and covenants typical for an arrangement of similar nature to the Partnership and will supersede the LOI.



With more than 1,000 clients served internationally, over 15,000 projects successfully completed and offices in Canada and the United States, dicentra is a leading consulting firm with 16 years of experience providing regulatory and compliance services.

"Bringing dicentra's experience and expertise to Abattis will help us to secure world-class regulatory and compliance services for Abattis and our clients and partners", stated Rob Abenante, President and CEO of Abattis.

"The Partnership will support our commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States", added Mr. Abenante.

"After more than 16 years of experience working with Health Canada's regulatory framework and the US Food and Drug Administration (FDA), we feel confident dicentra has the necessary experience and expertise needed to support Abattis's expansion plans", stated Dr. Karol Wojewnik, Vice President of Business Development (Life Sciences) at dicentra.

"The Partnership, paired with our state-of-the-art analytical services, will represent an additional step towards vertically integrating a full suite of world-class services for our clients", stated Dr. David Galvez, Senior Science Advisor at Abattis.

About dicentra

dicentra is a professional consulting firm that specializes in addressing all matters related to safety, quality and compliance for all product categories in the life sciences and food industries.

Since inception in 2002, dicentra has completed over 15,000 projects and serviced nearly 1000 companies internationally.

About Abattis

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD OF

ABATTIS BIOCEUTICALS CORP.,

"Rob Abenante"

Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the proposed Partnership; that dicentra’s experience and expertise will help Abattis secure world-class regulatory and compliance services for Abattis and its clients and partners; that the Partnership will support Abattis’s commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States; and that the Partnership, paired with Abattis’s state-of-the-art analytical services, will represent an additional step towards vertically integrating a full suite of world-class services for Abattis’s clients. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that a definitive agreement respecting the Partnership will not be entered into or that the Partnership will not be formed; that dicentra’s experience and expertise will not help Abattis secure world-class regulatory and compliance services for Abattis and its clients and partners; that the Partnership will not support Abattis’s commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States; that the Partnership, paired with Abattis’s state-of-the-art analytical services, will not represent an additional step towards vertically integrating a full suite of world-class services for Abattis’s clients; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.